Healthcare Startup Laboratoy work visual


A | B | C | D | EFG | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

ABBA Therapeutics AG
ABBA Therapeutics develops therapeutic antibodies against novel targets for cancer immunotherapy.

Alibion is a pre-clinical stage drug-development company developing the first personalized therapy against Rheumatoid arthritis.

Alentis Therapeutics AG
Alentis Therapeutics is a biotech based in Basel, Switzerland. It discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).

Anaveon is a late pre-clinical phase biotech based in Basel, Switzerland.  It focuses on the development of next generation IL-2 based therapeutic antibodies for tumor immunotherapy in melanoma, kidney carcinoma and lung cancer.

Avicenna Oncology
Avicenna Oncology GmbH is a biotechnology start-up, created in 2014 in Basel, Switzerland. Our lead program consists of ImmunoPayloads (ImPs), First In Class immuno-oncology therapeutics with a unique and innovating mode of action.

β-catenin project
The beta catenin project aims to develop novel therapeutics for the treatment of colorectal, lung, liver, breast, brain and ovarian cancers by removing pathological proteins from the human body.

Biotech in stealth modeBiotech in stealth mode
Developing novel cell engineering-based treatments.


Biotech in stealth modeBiotech in stealth mode
Discovery and development of new eye therapeutics for diseases with unmet medical need.

Biotech in stealth modeBiotech in stealth mode
Developing a novel digital therapeutic for the treatment of migraine.


Biotech in stealth modeBiotech in stealth mode
Company in stealth mode developing an antibody-based tumor therapy against a first-in-class target in the tumor microenvironment.

Biotech in stealth modeBiotech in stealth mode
Company in stealth mode developing novel inibitors of the inflammasome.


Biotech in stealth modeBiotech in stealth mode
Platform for finding new targets and developing novel drugs for solid cancers.


CellSpring analyzes human cells grown in special 3-Dimensional environments to develop new tools for diagnosing early-stage cancer.

CMET Pharmaceuticals
CMET Pharmaceuticals aims to develop novel therapies for the treatment of metastatic cancers, tailored to target circulating tumour cell clusters.

Cureab develops antibodies for cancer therapy focussing on lung, liver and colorectal cancer.

Epibloc applies a proprietary immunoprofiling platform to identify peptides that bind to specific autoantibodies involved in autoimmune diseases. The peptides are then used to develop companion diagnostics and precision drugs to eliminate only the disease causing autoantibodies.

FoRx Therapeutics is developing therapeutics that exploit the presence of DNA replication STRESS in human cancers.

GEBAMO is bringing CRISPR-Cas12a technology forward.

ImmProfile is advancing innovative discoveries and solutions in immune oncology.

Innervation Pharmaceuticals
Innervation Pharmaceuticals is a pre-clinical phase biotech. Its patented, solid-phase transfection platform is used for genome-wide screening services and the discovery of genes that boost neuronal regrowth after spinal cord injury.

INSIDER Therapeutics
INSIDER Therapeutics is a preclinical stage spin-off project from University of Zurich. It is developing first-in-class small molecule anticancer therapeutics that modulate the epitranscriptomic code.

ISARNA is a clinical stage Biotech Company, addressing high unmet medical need in Ophthalmology and beyond by developing innovative, targeted, first in class antisense blockbuster therapies for major blinding diseases.

logo Pattern BiosciencesPattern Biosciences

Next generation programmable therapies powered by Synthetic Biology.

PharmaBiome pioneers bacterial mixes as microbiome therapeutics in IBD and oncology based on our mixed-culture technology.

Polyneuron Pharmaceuticals AG
Polyneuron is committed to the development of a promising new drug class to treat autoimmune disorders.

SiBreaX develops stimulus responsive silicate-based nano-/microparticles for targeted drug/compound delivery and degradable, injectable nanocomposite hydrogels for biomedical and topical applications. Leveraging its platform technology of nano-/microparticles and hydrogels, SiBreaX partners in development as well as develops own drugs and medical hydrogels.

SunRegen Healthcare AG
SunRegen develops novel drugs for neurodegenerative diseases.

Synendos-TherapeuticsSynendos Therapeutics
We develop new drugs to treat anxiety and stress disorders by modulating the activity of cannabinoid molecules already present in the brain.

Synoesis is developing a first-in-class therapeutic to stop Parkinson’s disease.

T3 Pharmaceuticals AG
T3 Pharma develops the next generation bacterial cancer therapy.

The mission of TEPTHERA is to offer individualized therapeutic cancer vaccines.

TOLREMO is a cancer drug resistance company. Our resistance-preventing small molecules boost the long-term efficacy of existing cancer drugs to prolong patient survival.

VERSAMEB is a regenerative medicine research and development company.